News Releases

Date Title and Summary View
July 13, 2021
– FDA End-of-Phase 2 Meeting on KVD900 Oral HAE Phase 3 Program Scheduled for Late Q3 2021 – – FDA Response Submission for KVD824 Phase 2 Clinical Hold Expected Q3 2021 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 13, 2021-- KalVista Pharmaceuticals, Inc....
Additional Formats
July 12, 2021
– Phase 2 data for KVD900 in late-breaking session at European Academy of Allergy and Clinical Immunology (EAACI) Congress – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 12, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...
Additional Formats
June 28, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 28, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of multiple...
Additional Formats
June 5, 2021
– KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 5, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...
Additional Formats
May 27, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 27, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a...
Additional Formats
May 10, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 10, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of an...
Additional Formats
May 3, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 3, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul...
Additional Formats
April 20, 2021
– KVD824 Phase 2 on Clinical Hold – – Planning for KVD900 Phase 3 Unaffected – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 20, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization...
Additional Formats
March 19, 2021
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 19, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has...
Additional Formats
March 11, 2021
– Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant – – IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 – – Following Upsized Public Offering, Funded to KVD900 NDA Filing – CAMBRIDGE, Mass....
Additional Formats
Displaying 1 - 10 of 15